The US Oncology Network | Strategic Alliance Partners

Latest from The US Oncology Network

Digital Health and Process Improvements Enhance Community-Based Patient Care

October 20, 2021

A marked reduction in hospitalizations and emergency department visits are key metrics for value-based care programs. Quality improvement processes and electronic patient management systems may give practices a way to fully embrace these programs and remain mindful of cost while ensuring that patients receive high-quality care.

Coleman Centers the Discussion on Practice-Affirming ASCO Trials in Gynecologic Oncology

June 29, 2021

Practice-validating trials in cervical cancer, endometrial cancer, and ovarian cancer were the focus of the 2021 ASCO Annual Meeting in gynecologic oncology, each carrying relevant implications on extended therapy, surveillance, and biomarker testing.

The US Oncology Network Highlights Success With Oncology Care Model

June 10, 2021

Practices participating in the Oncology Care Model, an experimental payment model developed by the Center for Medicare and Medicaid Innovation, are incentivized to improve patient experiences and outcomes by providing enhanced services and care while bending the total cost curve.

US Oncology Network Continues Its Rapid Growth and Enhances Surgical Expertise

April 02, 2021

The US Oncology Network, the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, continues to expand its reach into local communities while broadening its surgical expertise with the addition of physicians from Texas Colon & Rectal Specialists, a large colorectal practice in North Texas, as a part of Texas Oncology, a practice in The Network.

Dr. Rifkin on Split Dosing of Daratumumab in Myeloma

January 04, 2019

Robert M. Rifkin, MD, attending physician, Rocky Mountain Cancer Centers, research lead, Multiple Myeloma, The US Oncology Network, discusses a trial looking at split dosing of daratumumab in myeloma.

A Perfect Storm Brews for Biosimilar Marketing

October 03, 2018

Pressure to reduce costs associated with biologics is one of the forces driving the rapid expansion of biosimilars, which are biological drugs that are very similar to already approved reference biologics in terms of potency, safety, and efficacy.